These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 8392397

  • 1. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.
    Pastores GM, Sibille AR, Grabowski GA.
    Blood; 1993 Jul 15; 82(2):408-16. PubMed ID: 8392397
    [Abstract] [Full Text] [Related]

  • 2. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 15; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 3. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct 15; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 4. Enzyme augmentation in moderate to life-threatening Gaucher disease.
    Fallet S, Grace ME, Sibille A, Mendelson DS, Shapiro RS, Hermann G, Grabowski GA.
    Pediatr Res; 1992 May 15; 31(5):496-502. PubMed ID: 1603627
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

  • 6. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun 01; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 7. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 01; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 8. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C.
    J Inherit Metab Dis; 2013 May 01; 36(3):543-53. PubMed ID: 22976765
    [Abstract] [Full Text] [Related]

  • 9. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
    Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO.
    Ann Intern Med; 1995 Jan 01; 122(1):33-9. PubMed ID: 7985893
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.
    Schiffmann R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI.
    Blood Cells Mol Dis; 2002 Jan 01; 28(2):288-96. PubMed ID: 12064924
    [Abstract] [Full Text] [Related]

  • 12. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 01; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD.
    Br J Haematol; 2012 Aug 01; 158(4):528-38. PubMed ID: 22640238
    [Abstract] [Full Text] [Related]

  • 14. Rebound hepatosplenomegaly in type 1 Gaucher disease.
    Tóth J, Erdos M, Maródi L.
    Eur J Haematol; 2003 Feb 01; 70(2):125-8. PubMed ID: 12581195
    [Abstract] [Full Text] [Related]

  • 15. [Gaucher disease type I diagnosed at 63 years old presenting with thrombocytopenia].
    Kawahara S, Kato A, Oshimi K, Ida H.
    Rinsho Ketsueki; 2008 May 01; 49(5):335-9. PubMed ID: 18572811
    [Abstract] [Full Text] [Related]

  • 16. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, Mistry PK.
    Indian Pediatr; 2011 Oct 01; 48(10):779-84. PubMed ID: 22080680
    [Abstract] [Full Text] [Related]

  • 17. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 18. [Response criteria for enzyme substitution in Gaucher disease].
    Berthold F, Sieverts H, Benz-Bohm G, Landwehr P, Harzer K.
    Monatsschr Kinderheilkd; 1992 Oct 20; 140(10):740-4. PubMed ID: 1331780
    [Abstract] [Full Text] [Related]

  • 19. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 20; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 20. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec 20; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.